Stephen Hahn, FDA commissioner (AP Images)

Stephen Hahn: FDA will make some changes amid Covid-19 per­ma­nent

The FDA will look to per­ma­nent­ly im­ple­ment some of the process­es and poli­cies adopt­ed in its re­sponse to the Covid-19 pan­dem­ic, FDA com­mis­sion­er Stephen Hahn said dur­ing a vir­tu­al brief­ing host­ed by the Al­liance for a Stronger FDA on Mon­day.

Hahn’s state­ments dur­ing the brief­ing close­ly mir­rored state­ments he made in a pre-record­ed video FDA up­loaded to YouTube on Fri­day.

“As this pan­dem­ic has evolved, it was clear to all of us that some FDA process­es need­ed to be ad­just­ed to ac­com­mo­date the ur­gency of the pan­dem­ic and I think the en­tire FDA team has now seen first-hand that we need to take a crit­i­cal look at some of our process­es and poli­cies,” Hahn said.

Hahn added that many of the changes the agency will im­ple­ment “rep­re­sent an ac­cel­er­a­tion of where we were head­ed be­fore,” and in­clude sup­port for de­cen­tral­ized clin­i­cal tri­als, greater use of telemed­i­cine tech­nol­o­gy in clin­i­cal tri­als and work re­lat­ed to lab­o­ra­to­ry-de­vel­oped tests.

Hahn said he has in­struct­ed FDA staff “to iden­ti­fy the lessons learned from this pan­dem­ic and what ad­just­ments may be need­ed, not just to man­age this or fu­ture emer­gen­cies, but how to per­ma­nent­ly make FDA more ef­fi­cient in car­ry­ing out [its] reg­u­la­to­ry re­spon­si­bil­i­ties.”

Ad­di­tion­al­ly, Hahn said FDA is us­ing re­al-world ev­i­dence to mon­i­tor the use of med­ical prod­ucts dur­ing the pan­dem­ic. “We very much used re­al-world ev­i­dence and our Sen­tinel sys­tem and oth­er re­sources to look back at the re­al-world use of di­ag­nos­tic tests and med­ical prod­ucts and then ad­just our au­tho­riza­tions based on that,” he said, adding that re­al-world ev­i­dence can al­so help “to bet­ter un­der­stand dis­ease, de­scribe and mea­sure im­mu­ni­ty [and] un­der­stand the op­er­at­ing char­ac­ter­is­tics of tests.”

Hahn al­so ad­dressed con­flict of in­ter­est con­cerns stem­ming from the role of Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) Di­rec­tor Janet Wood­cock and Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) Di­rec­tor Pe­ter Marks in over­see­ing the re­view of prod­ucts de­vel­oped to treat or pre­vent Covid-19.

Wood­cock and Marks were both ini­tial­ly slat­ed to take lead­er­ship roles on the Trump ad­min­is­tra­tion’s Op­er­a­tion Warp Speed. Short­ly af­ter the an­nounce­ment, Marks left his new role to fo­cus on head­ing CBER, while Wood­cock was tem­porar­i­ly re­as­signed to the Of­fice of the Com­mis­sion­er dur­ing her work on Op­er­a­tion Warp Speed.

“We have been very clear in writ­ing, but al­so ver­bal­ly, that we will main­tain our reg­u­la­to­ry in­de­pen­dence, so that Janet [Wood­cock] will not par­tic­i­pate in the reg­u­la­to­ry de­ci­sions around ther­a­peu­tics and Pe­ter and I will stay out­side of any de­ci­sion-mak­ing that Op­er­a­tion Warp Speed has to make with re­spect to med­ical prod­ucts so that we can main­tain our in­de­pen­dence,” Hahn said.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

The End­points 11: They've got mad mon­ey and huge am­bi­tions. It's time to go big or go home

These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma. I’ve had a couple of faceplants earlier this year, watching some of the biotechs on my short list choose a quick leap onto Nasdaq or into the arms of a buyer.

Vividion, you would have been a great pick for the Endpoints 11. I’m sorry I missed you.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA au­tho­rizes Pfiz­er's vac­cine boost­er for se­niors, those at high risk for se­vere Covid-19

The Biden administration’s goal of kicking off its booster shot drive for the entire US population this week is not quite going as planned.

First, Pfizer applied for approval of a supplemental application for the booster shots, but since last Friday’s adcomm reviewing them, the plan has devolved into an EUA, which the FDA issued late Thursday evening.

The population that is now eligible for the booster, six months after receiving the first pair of Pfizer-BioNTech vaccines, also narrowed from what Pfizer applied for (everyone who’s eligible for the initial Pfizer shots) to just those who are 65 or older, or at high-risk of a Covid infection, including health care workers and others with occupational hazards.

Stéphane Bancel, AP Images

Fi­nal analy­sis of US-fund­ed Mod­er­na Covid vac­cine tri­al shows 98% ef­fi­ca­cy against se­vere dis­ease

A final look at the results of the placebo-controlled Moderna trial in the New England Journal of Medicine, published Thursday afternoon, shows how the vaccine continues to prevent Covid-19 and severe cases after more than five months following the second shot.

Of the more than 30,000 enrolled in the trial that ultimately led to the vaccine’s EUA, only two people in the vaccine group got a severe form of the disease, compared to 106 in the placebo group — leading to an efficacy of 98%.

Dave Lennon, former president of Novartis Gene Therapies

So what hap­pened with No­var­tis Gene Ther­a­pies? Here's your an­swer

Over the last couple of days it’s become clear that the gene therapy division at Novartis has quietly undergone a major reorganization. We learned on Monday that Dave Lennon, who had pursued a high-profile role as president of the unit with 1,500 people, had left the pharma giant to take over as CEO of a startup.

Like a lot of the majors, Novartis is an open highway for head hunters, or anyone looking to staff a startup. So that was news but not completely unexpected.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Who are the women su­per­charg­ing bio­phar­ma R&D? Nom­i­nate them for this year's spe­cial re­port

The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech employees around the world, they occupy very few places in C-suites, and even fewer make it to the helm.

Some companies are listening, according to a recent BIO survey which showed that this year’s companies were 2.5 times more likely to have a diversity and inclusion program compared to last year’s sample. But we still have a long way to go. Women represent just 31% of biotech executives, BIO reported. And those numbers are even more stark for women of color.

FDA+ roundup: Bs­U­FA III ready for show­time, court tells FDA to re-work com­pound­ing plan, new guid­ance up­dates and more

The FDA has now spelled out what exactly will be included in the third iteration of Biosimilar User Fee Act (BsUFA) from 2023 through 2027, which similarly to the prescription drug deal, sets fees that industry has to pay for submitting applications, in exchange for firm timelines that the agency must meet.

This latest deal includes several sweeteners for the biosimilar industry, which has yet to make great strides in the US market, with shorter review timelines for safety labeling updates and updates to add or remove an indication that does not contain efficacy data.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

When ef­fi­ca­cy is bor­der­line: FDA needs to get more con­sis­tent on close-call drug ap­provals, agency-fund­ed re­search finds

In the exceedingly rare instances in which clinical efficacy is the only barrier to a new drug’s approval, new FDA-funded research from FDA and Stanford found that the agency does not have a consistent standard for defining “substantial evidence” when flexible criteria are used for an approval.

The research comes as the FDA is at a crossroads with its expedited-review pathways. The accelerated approval pathway is under fire as the agency recently signed off on a controversial new Alzheimer’s drug, with little precedent to explain its decision. Meanwhile, top officials like Rick Pazdur have called for a major push to simplify and clarify all of the various expedited pathways, which have grown to be must-haves for sponsors of nearly every newly approved drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.

Emma Walmsley, GlaxoSmithKline CEO (Credit: Fang Zhe/Xinhua/Alamy Live News)

The fire un­der Glax­o­SmithK­line's Em­ma Walm­s­ley grows as an­oth­er well-known ac­tivist in­vestor grabs its pitch­fork — re­port

Bluebell Capital Partners, a proxy brawler fresh off a campaign to oust global food giant Danone’s CEO and most of its board of directors, has bought a stake in UK drugmaker GlaxoSmithKline with its eyes trained directly on Emma Walmsley, the Financial Times reported Wednesday.

The London-based hedge fund joins another notorious activist firm in Paul Singer’s Elliott Management, which earlier this year called for a shakeup in leadership at GSK to handle what the company described as a wealth of riches across the drug giant’s portfolio hindered by limited vision from top staff.